Improvement in Radiomic Features Following Bridging Therapy is Prognostic for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome. - Hubbeling, H.G.; Leithner, D.; Silverman, E.A.; Flynn, J.; Devlin, S.; Shah, G.L.; Fregonese, B.; Bedmutha, A.; Boardman, A.; Dahi, P.B.; Lin, R.J.; Park, J.H.; et al. (International Journal of Radiation Oncology, Biology, Physics, 2024)